Sunny Mok

Sunny Mok has over 16 years of experience in the biopharmaceutical industry. In 2021, they began working as the VP of Program Management at Scribe Therapeutics. From 2019 to 2021, they worked as the Director/Associate Director of Project and Portfolio Management at Gilead Sciences, where they managed cross-functional drug development programs in the Inflammation therapeutic area and provided program management leadership into disease area, program and project strategy and vision. From 2018 to 2019, they were the Associate Director of Translational Science at AstraZeneca, where they led a project management group and chaired an innovation group. From 2009 to 2018, they worked at MedImmune, where they held various roles, including Senior Manager of Translational Science, Scientist II of Translational Science, and Scientist I of Research. From 2005 to 2009, they were a Research Fellow in Pediatric Infectious Disease at Vanderbilt University Medical Center.

Sunny Mok holds a Master of Business Administration (MBA) from the University of California, Berkeley, Haas School of Business, a PhD in Bioengineering from Rice University, and a BS in Chemical Engineering and Biochemistry from the University of Wisconsin-Madison.